Atea Pharmaceuticals
AVIR
AVIR
107 hedge funds and large institutions have $169M invested in Atea Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 45 increasing their positions, 30 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
107
Holders Change
-11
Holders Change %
-9.32%
% of All Funds
1.57%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
11
Increased
45
Reduced
30
Closed
21
Calls
$292K
Puts
$169K
Net Calls
+$123K
Net Calls Change
-$59K
Top Buyers
| 1 |
BlackRock
New York
|
+$3.82M |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$2.02M |
| 3 |
Morgan Stanley
New York
|
+$1.68M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.45M |
| 5 |
Barclays
London,
United Kingdom
|
+$523K |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.36M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.69M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$1.8M |
| 4 |
Vontobel Holding
Zurich,
Switzerland
|
-$1.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.26M |
